by 
Market Overview:
Personalized gene therapy involves modifying a patient’s own immune cells or other cells to target and destroy cancer. These therapies utilize various approaches such as chimeric antigen receptor T-cell (CAR T-cell) therapy, T cell receptor therapy, oncolytic virus therapy, and neoantigen vaccine therapy. They have shown promising results in clinical trials for certain types of cancers including hematological and solid tumors. Its customized nature allows oncologists to address individual tumor characteristics and improve treatment outcomes.
The Personalized Gene Therapy Treatments for Cancer Market is estimated to be valued at US$ 2.20 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The rising prevalence of various cancers globally is a major factor driving the growth of the personalized gene therapy treatments for cancer market. Around 1 in 6 deaths in the US are due to cancer. Also, the number of new cancer cases is projected to rise to over 29 million by 2050 according to WHO, signifying a large patient pool eligible for these personalized therapies. Secondly, the improving clinical trials results and continued FDA approvals is stimulating increased adoption of these therapies. For instance, positive phase 2 trial results of Kymriah and Yescarta led to their FDA approval for acute lymphoblastic leukemia and lymphoma respectively in 2017.
Segment Analysis
The personalized gene therapy treatments for cancer market is dominated by the segment of CAR-T therapies where T-cells from the patient’s blood are genetically modified to express a Chimeric Antigen Receptor (CAR) that targets tumor surface antigens. CAR-T therapies have emerged as a promising therapeutic approach for blood cancer and certain types of solid tumors. However, challenges remain in terms of side effects, resistance issues and high treatment costs. The genetic enhancement of T-cell receptors (TCR) therapies segment is expected to witness growth in coming years as it addresses some limitations of CAR-T.
PEST Analysis
Political: Regulations around gene and cell therapies are evolving. Approvals for some major therapies have provided momentum. However, cross-border regulations and inconsistencies still hinder developments.
Economic: High costs remain a challenge due to extensive research requirements and customized manufacturing needs. Increasing funding from governments and philanthropic organizations is helping address the issue.
Social: Acceptance of gene therapies is increasing. However, some degree of resistance from patients due to fear of unknown effects remains a concern.
Technological: Advancements in vector engineering, delivery systems, and manufacturing are enabling more precise and safe modifications. CRISPR-Cas9 based genome editing is opening new avenues.
Key Takeaways
The global personalized gene therapy treatments for cancer market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing incidence of cancer and approval of advanced therapies. The market size for 2023 is projected to reach US$ 2.20 Bn.
Regionally, North America dominates the market currently due to strong presence of key players and favorable reimbursements. Asia Pacific is anticipated to be the fastest growing market over the forecast period due to rising healthcare investments, increasing cancer burden and growing focus on niche therapy areas.
Key players operating in the personalized gene therapy treatments for cancer market are Novartis AG, Kite Pharma (Gilead Sciences), Spark Therapeutics (Roche), and bluebird bio. Novartis has established leadership in CAR-T therapies with Kymriah approval for certain leukemias and lymphomas. Kite Pharma received approval for Yescarta for non-Hodgkin’s lymphoma. Spark and bluebird bio are developing gene therapies for hematological and solid tumors.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
